Effective communications are a vital component of an efficient clinical development program. Successfully communicating the value of clinical studies to investigators and patients has a favorable impact on trial costs and timelines. Effective clinical communications can not only add billions of dollars to a company’s top-line growth, they can also have a critical impact on the bottom-line during pharmaceutical product development.
Pharmaceutical companies look to Best Practices, LLC to help them understand the key drivers affecting their ability to deliver targeted, effective communications through appropriate channels.
Through research for client companies, Best Practices, LLC has analyzed practices that use marketing techniques to profile patients and investigators for better site selection, developing effective positioning and training messages to recruit and prepare study sites, and supporting study sites in recruiting and retaining patients.
Our research expertise in clinical communications effectively positions us to help your organization identify key practices to expedite clinical development and hold down costs.
Pharmaceutical and diagnostic company partnerships will become a necessity as disease knowledge expands and therapeutic interventions become more specific and customized to individual patients. Genetic discoveries and regulatory concerns have created an environment where pharmaceutical
companies need diagnostic industry partners to realize the full potential of a product – or in some cases to even gain approval to market a drug in the first place. Likewise, diagnostic companies could potentially reap great benefits from partnerships in the form of increased clinical development and marketing support for a new test, leading to quicker times to market.
Our research expertise in this area can help your organization understand how to use diagnostic tests to support the clinical development program of a pharmaceutical product. Previous research by Best Practices, LLC, analysts in this area includes the development and marketing of different tests, the establishment of these tests within the medical community, and the integrated activities between diagnostic/prognostic tests and therapeutic compounds.
Pharmaceutical companies want to develop a greater understanding of disease markets during the clinical development process. Determining what protocols are currently used to diagnose a given disease, identifying key decision makers in the diagnosis and treatment processes, locating patients and determining how a diagnostic might enhance the value and market acceptance of a new therapeutic compound are all important issues for a company entering the clinical development phase.
Best Practices, LLC is ideally suited to assist companies in addressing these critical issues based on our depth of experience in conducting benchmarking studies and in mapping patient flow in leading healthcare institutions. Best Practices LLC's patient flow maps are used in clinical development to design studies and find patients.
With expertise in both pharmaceuticals and diagnostics, Best Practices, LLC recently undertook a research project for a leading international company developing a new compound for treatment of a severe disease. Best Practices, LLC built and examined the pathways of affected patients through leading medical centers. Resulting patient flow maps positioned the client to design effective clinical studies around its compound.